{"id":828110,"date":"2025-03-20T10:08:16","date_gmt":"2025-03-20T14:08:16","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/optn-alert-monsey-firm-of-wohl-fruchter-investigating-fairness-of-the-sale-of-optinose-to-paratek-pharmaceuticals\/"},"modified":"2025-03-20T10:08:16","modified_gmt":"2025-03-20T14:08:16","slug":"optn-alert-monsey-firm-of-wohl-fruchter-investigating-fairness-of-the-sale-of-optinose-to-paratek-pharmaceuticals","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/optn-alert-monsey-firm-of-wohl-fruchter-investigating-fairness-of-the-sale-of-optinose-to-paratek-pharmaceuticals\/","title":{"rendered":"OPTN Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of OptiNose, to Paratek Pharmaceuticals"},"content":{"rendered":"
\n

MONSEY, N.Y., March 20, 2025 (GLOBE NEWSWIRE) — The law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of OptiNose, Inc. (Nasdaq: OPTN) (\u201cOptiNose\u201d) to Paratek Pharmaceuticals (\u201cParatek\u201d) for $9.00 per share in cash, plus a contingent value right (\u201cCVR\u201d) worth $5.00 per share payable in the event that certain net revenue milestones are achieved by OptiNose\u2019s flagship drug, XHANCE.<\/p>\n

Notably, as detailed below, the sale price is below the price target for OptiNose of at least three Wall Street analysts even including the CVR (source: TipRanks).<\/p>\n

Additionally, the sale price is well below OptiNose\u2019 52-week high of $25.80, and thus the deal appears highly opportunistic.<\/p>\n

If you remain an OptiNose shareholder and question the fairness of the price, you may contact our firm at the following link to discuss your legal rights at no charge:<\/p>\n

\n https:\/\/wohlfruchter.com\/cases\/optinose\/<\/a>\n <\/p>\n

Alternatively, you may contact us by phone at 866-833-6245, or via email at alerts@wohlfruchter.com<\/a>.<\/p>\n

\n Why is there an investigation?<\/strong>
\n
On March 20, 2025, OptiNose announced that it had agreed to be sold to Paratek for $9.00 per share in cash, plus a CVR worth $5.00 per share payable in the event that certain net revenue milestones are achieved by OptiNose\u2019s flagship drug, XHANCE.<\/p>\n

Notably, the sale price is below the price target for OptiNose of at least three Wall Street analysts even including the CVR:<\/p>\n